Treatment of HIV infection with the CCR5 antagonist maraviroc.
about
Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitorsA topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu miceDevelopment and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.Maraviroc attenuates trauma-hemorrhage-induced hepatic injury through PPAR gamma-dependent pathway in ratsAntibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgGN-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.Physiology and pharmacology of plerixafor.Chemokine receptor modeling: an interdisciplinary approach to drug design.Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.
P2860
Q28477409-6E37D018-DA8E-46DD-85E1-A6BC81A3FDECQ28478394-83BB15B6-F908-4E51-935E-6CCDFB47B5E4Q33643626-4873F261-A64A-4859-8309-8870D0246C3AQ33784852-F8A99B28-9DC4-41F0-9E9C-5AB0DA641977Q34367158-4465F922-5C0B-4D3B-A885-D78EC9D6E720Q34536817-7C778C77-7F61-4398-84D2-E64ADB4710BCQ34801630-B5C97AE8-CE6C-44E0-B014-D19EB7A75E1DQ35036778-D5E3069E-5B88-47BD-A47E-EC28C066ED40Q36759899-A97242A5-09BB-4649-BA27-90C154D851D9Q37790697-03F997D5-FE4D-4062-AD6B-6768453BE1F8Q38157897-3C792227-5C64-4A7D-B509-462BD6966D2DQ38172960-994BA840-5336-4A7F-9C1E-E3B9FB06F806Q39079796-E05431E3-5AEE-4125-84A2-B8EFECF6D47FQ39944975-17367156-B7C2-4177-A9CC-B77163FCCF64Q41846910-62EA7E32-87DB-4CBE-BF54-E475C5D9947A
P2860
Treatment of HIV infection with the CCR5 antagonist maraviroc.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of HIV infection with the CCR5 antagonist maraviroc.
@en
Treatment of HIV infection with the CCR5 antagonist maraviroc.
@nl
type
label
Treatment of HIV infection with the CCR5 antagonist maraviroc.
@en
Treatment of HIV infection with the CCR5 antagonist maraviroc.
@nl
prefLabel
Treatment of HIV infection with the CCR5 antagonist maraviroc.
@en
Treatment of HIV infection with the CCR5 antagonist maraviroc.
@nl
P2093
P2860
P1476
Treatment of HIV infection with the CCR5 antagonist maraviroc.
@en
P2093
Alwin D R Huitema
Jan Willem Mulder
Wiete Kromdijk
P2860
P304
P356
10.1517/14656561003801081
P407
P577
2010-05-01T00:00:00Z